Status:
COMPLETED
The Lymphoma and Leukemia Society Amended COVID-19 Registry
Lead Sponsor:
Lymphoma and Leukemia Society
Conditions:
Covid19
Eligibility:
All Genders
21+ years
Brief Summary
The LLS COVID-19 Registry is being amended to invite people who participated in the LLS COVID-19 Registry and did not develop antibodies after receiving a complete COVID-19 vaccination, as well as peo...
Detailed Description
The results of the Leukemia and Lymphoma Society (LLS) COVID-19 Registry indicate that about twenty-five percent (25%) of people with blood cancer and on immunosuppressants participating in the LLS CO...
Eligibility Criteria
Inclusion
- People with blood cancer who did not develop antibodies after a complete COVID-19 vaccination.
Exclusion
- People who receiived a complete COVID-19 vaccination and did develop antibodies.
- People unwilling or unable to receive COVID-19 booster.
Key Trial Info
Start Date :
August 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 13 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04794387
Start Date
August 27 2021
End Date
December 13 2022
Last Update
March 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lymphoma and Leukemia Society
Rye Brook, New York, United States, 10573